Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Want to see SRPT full AI Analyst Report?
SRPT Stock Chart & Stats
$21.55
$1.44(1.16%)
At close: 4:00 PM EST
$21.55
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $44.14
Previous CloseN/A
Volume185.86K
Average Volume (3M)3.03M
Market Cap
$2.11B
Enterprise Value$2.68B
Total Cash (Recent Filing)$653.19M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)1.7
Beta1.13
Next Earnings
Aug 05, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding105,576,225
10 Day Avg. Volume2,217,550
30 Day Avg. Volume3,033,687
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.23
Enterprise Value/Gross Profit1.97
Enterprise Value/Ebitda22.03
Forecast
1Y Price Target
$21.68Price Target Upside0.61% Upside
Rating ConsensusHold
Number of Analyst Covering24
EPS Forecast (FY)3
Revenue Forecast (FY)$1.72B
Bulls Say, Bears Say
Bulls Say
Clinical Endorsement And Trial ExpansionRoche's decision to initiate a global Phase 3 study outside the U.S. reflects external confidence in Elevidys' clinical potential and could validate efficacy in a randomized setting.
Commercial ExecutionRenewed U.S. promotion, an expanded sales force, and favorable views from key opinion leaders are positioned to increase Elevidys adoption and support commercial performance.
Delivery Technology AdvantageTRiM delivery and siRNA candidates have produced higher muscle concentrations and dose-dependent exposure, supporting stronger target engagement that could translate into better patient outcomes if confirmed in later studies.
Bears Say
Efficacy CredibilityThe earlier Phase 3 EMBARK trial failed to meet its primary movement endpoint, creating doubt about consistent functional benefit and weakening confidence in future efficacy claims.
Placebo-controlled Trial RiskA new placebo-controlled study raises the chance that Elevidys will not demonstrate a clear benefit on the core movement test, which would undercut comparisons to external control groups.
Safety ConcernsSerious adverse events in early trials, including a fatal arrhythmia in a DM1 patient, heighten safety scrutiny and could slow development or prompt more stringent regulatory review.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $44.14 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.11B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 85 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on May 06, 2026. The company reported $2.88 earnings per share for the quarter, beating the consensus estimate of $0.976 by $1.904.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.23.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,576,225 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $2.88 in its last earnings report, beating expectations of $0.976. Following the earnings report the stock price went down -9.683%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.68 (0.61% Upside)
$21.68 (0.61% Upside)
Blogger Sentiment
Neutral
SRPT Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 33.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $123.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-59.93%
12-Months-Change
Fundamentals
Return on Equity
4.89%
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely constructive tone: Sarepta reported profitable Q1 results, strong gross margins, and a $748M cash balance while reiterating full-year guidance of $1.2B–$1.4B. The company highlighted meaningful clinical progress—notably robust early siRNA data (FSHD, DM1), encouraging EMBARK 3‑year and MRI evidence for Alevitus, regulatory progress with sNDA submissions, and commercialization initiatives (expanded sales force). Offsetting these positives were lower Alevitus product sales driving a modest YoY revenue decline (–2%), an information gap slowing demand recovery, short-term cash outflows tied to planned Arrowhead payments, and unresolved safety/regulatory uncertainty for non‑ambulatory Alevitus use that depends on small open‑label cohorts. Overall, the call emphasized stabilization and long‑term opportunity but signaled that commercial recovery for Alevitus will be gradual and that some clinical/regulatory risks remain.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$21.68
▲(0.61% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
5.13% Insiders
16.23% Mutual Funds
1.39% Other Institutional Investors
47.28% Public Companies and
Individual Investors